<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Citius Oncology, Inc. — News on 6ix</title>
<link>https://6ix.com/company/citius-oncology-inc</link>
<description>Latest news and press releases for Citius Oncology, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/citius-oncology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355a8f78dffbe2df0eb872.webp</url>
<title>Citius Oncology, Inc.</title>
<link>https://6ix.com/company/citius-oncology-inc</link>
</image>
<item>
<title>Citius Oncology Ships First International Order of LYMPHIR™ to Europe</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-ships-first-international-order-of-lymphirtm-to-europe</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-ships-first-international-order-of-lymphirtm-to-europe</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients throu</description>
</item>
<item>
<title>Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-announces-a-registered-direct-offering-of-dollar5-million-priced-at-the-market-under-nasdaq-rules-1</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-announces-a-registered-direct-offering-of-dollar5-million-priced-at-the-market-under-nasdaq-rules-1</guid>
<pubDate>Fri, 24 Apr 2026 04:00:00 GMT</pubDate>
<description>CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company</description>
</item>
<item>
<title>Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-provides-commercial-update-on-lymphirtm-launch-highlighting-early-adoption-and-expanding-clinical-development-3</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-provides-commercial-update-on-lymphirtm-launch-highlighting-early-adoption-and-expanding-clinical-development-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March</description>
</item>
<item>
<title>Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-to-participate-in-usclc-annual-workshop-2026-highlighting-lymphirtm-in-discussions-with-leading-cutaneous-lymphoma-experts</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-to-participate-in-usclc-annual-workshop-2026-highlighting-lymphirtm-in-discussions-with-leading-cutaneous-lymphoma-experts</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings availableCRANFORD, N.J.,</description>
</item>
<item>
<title>Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-positive-topline-results-from-investigatorinitiated-phase-1-study-of-lymphirtm-in-combination-with-pembrolizumab-in-relapsed-or-refractory-gynecologic-cancers-23</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-positive-topline-results-from-investigatorinitiated-phase-1-study-of-lymphirtm-in-combination-with-pembrolizumab-in-relapsed-or-refractory-gynecologic-cancers-23</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor</description>
</item>
<item>
<title>Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-preliminary-topline-phase-1-data-from-study-of-lymphirtm-e7777-dosing-prior-to-commercial-cart-therapy-in-highrisk-diffuse-large-bcell-lymphoma</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-preliminary-topline-phase-1-data-from-study-of-lymphirtm-e7777-dosing-prior-to-commercial-cart-therapy-in-highrisk-diffuse-large-bcell-lymphoma</guid>
<pubDate>Wed, 04 Mar 2026 14:15:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR‑T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma</description>
</item>
<item>
<title>Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-secures-dollar38-million-through-new-jersey-economic-development-program</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-secures-dollar38-million-through-new-jersey-economic-development-program</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Non-dilutive capital supports continued execution and value creationCRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius</description>
</item>
<item>
<title>Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-inc-announces-first-130000702</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-inc-announces-first-130000702</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-lymphirtm</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-lymphirtm</guid>
<pubDate>Fri, 13 Feb 2026 05:00:00 GMT</pubDate>
<description>Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial resultsCRANFORD, N.J.,</description>
</item>
<item>
<title>Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-expands-international-distribution-130000084</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-expands-international-distribution-130000084</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Uniphar ("Uniphar"), a leading international healthcare services company, to support access to LYMPHIR™ (denileukin diftitox-cxdl) outside the United States. This agreement represents Citius Oncology's third international distribution partnership and further adv</description>
</item>
<item>
<title>Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-inc-reports-fiscal-213000962</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-inc-reports-fiscal-213000962</guid>
<pubDate>Tue, 23 Dec 2025 21:30:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius</description>
</item>
<item>
<title>Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-closing-18-213000012</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-closing-18-213000012</guid>
<pubDate>Wed, 10 Dec 2025 21:30:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,284,404 shares of its common stock at a purchase price of $1.09 per share. In addition, the Company issued to the investor unregi</description>
</item>
<item>
<title>Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-18-million-133000680</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-18-million-133000680</guid>
<pubDate>Tue, 09 Dec 2025 13:30:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into a definitive agreement with a single healthcare-focused investor for the purchase and sale of 1,284,404 shares of its common stock at a purchase price of $1.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issu</description>
</item>
<item>
<title>Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-expands-lymphir-distribution-133700833</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-expands-lymphir-distribution-133700833</guid>
<pubDate>Thu, 04 Dec 2025 13:37:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of ad</description>
</item>
<item>
<title>Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-u-commercial-170000760</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-announces-u-commercial-170000760</guid>
<pubDate>Mon, 01 Dec 2025 17:00:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic ther</description>
</item>
<item>
<title>Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-exhibit-67th-american-130000466</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-exhibit-67th-american-130000466</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida.</description>
</item>
<item>
<title>Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-advance-commercial-launch-133700747</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-advance-commercial-launch-133700747</guid>
<pubDate>Fri, 21 Nov 2025 13:37:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's commercial team intends to further leverage Verix's innovative Tovana platform</description>
</item>
<item>
<title>Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-announces-a-registered-direct-offering-of-dollar60-million-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-pharmaceuticals-announces-a-registered-direct-offering-of-dollar60-million-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company</description>
</item>
<item>
<title>Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch</title>
<link>https://6ix.com/company/citius-oncology-inc/news/citius-oncology-signs-u-distribution-123700294</link>
<guid isPermaLink="true">https://6ix.com/company/citius-oncology-inc/news/citius-oncology-signs-u-distribution-123700294</guid>
<pubDate>Mon, 20 Oct 2025 12:37:00 GMT</pubDate>
<description>Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunoth</description>
</item>
</channel>
</rss>